Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a study titled ‘Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their Offspring.’ The study aims to evaluate pregnancy outcomes in women exposed to risankizumab, a drug used for conditions like plaque psoriasis and Crohn’s disease, compared to those not exposed. This research is significant as it seeks to understand the safety implications of risankizumab during pregnancy.
The intervention being tested is risankizumab, administered as a subcutaneous injection. It is designed to treat conditions such as plaque psoriasis, psoriatic arthritis, and Crohn’s disease. The study will compare outcomes between pregnant women exposed to this drug and those exposed to other similar medications.
This observational study follows a case-control model with a prospective time perspective. It does not involve any allocation or masking, focusing primarily on understanding the safety of risankizumab exposure during pregnancy.
The study began on July 30, 2021, with the last update submitted on July 15, 2025. These dates are crucial as they indicate the study’s progress and the timeline for data collection and analysis.
Market implications for AbbVie could be significant, as positive results might enhance investor confidence and potentially boost stock performance. The study’s outcomes could also influence the competitive landscape, particularly if risankizumab is proven safe for use during pregnancy, setting it apart from competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.